GLP‐1 agonists were developed as a glucose‐lowering treatment in type 2 diabetes; however, as a class, they are highly efficacious at lowering body weight, leading to FDA approval for the treatment of obesity in the absence of diabetes.74, 75. Here, GLP1R is linked to obesity disorder.